Table 3 Exosome-based circRNA delivery for cancer therapy
From: Recent advances of exosomal circRNAs in cancer and their potential clinical applications
Cancer | circRNAs | Source | Function | References |
|---|---|---|---|---|
SCLC | Circ-SH3PXD2A | Circ-SH3PXD2A-overexpressing cells | Decreased chemoresistance and cell proliferation | [198] |
Lung | Circ-RABL2B | Circ-RABL2B-overexpressing cells | Impoverished stemness, and promoted erlotinib sensitivity | [199] |
CRC | Circ-PTPRA | Circ-PTPRA transfected cells | Inhibited tumorigenesis and promoted radiosensitivity | [56] |
CRC | Circ-RHOBTB3 | ASOs treated CRC | Inhibited CRC growth and metastasis | [59] |
CRC | Circ-FBXW7 | circ-FBXW7-transfected FHC cells | Ameliorated chemoresistance to oxaliplatin | [89] |
CRC | Circ-EPB41L2 | Circ-EPB41L2 transfected cells | Inhibited proliferation and metastasis | [191] |
CRC | Circ_0094343 | NCM460 | Improved chemosensitivity | [194] |
HCC | Circ_0051443 | HL-7702 cell | Suppressed tumor progression | [57] |
HCC | Circ_0004658 | RBP-J-overexpressed- macrophage | Inhibited the progression | [61] |
HCC | Circ_0072088 | HCC cells | Suppressed the metastasis | [75] |
HCC | Circ-G004213 | / | Promoted cisplatin sensitivity | [91] |
PDAC | Circ_0006790 | BMSC | Inhibited growth, metastasis, and immune escape | [74] |
PDAC | Circ_0012634 | Pancreatic ductal epithelial cel1l | Restrained PDAC progression | [200] |
Gastric | Circ-ITCH | Circ-ITCH-transfected cells | Suppressed the metastasis | [76] |
Gastric | CircSTAU2 | GES-1 cells | Inhibited the progression | [77] |
Gastric | Circ_0017252 | GC cells | Inhibited macrophage M2 polarization | [201] |
Gastric | Circ-RELL1 | / | Suppressed the malignant behavior | [192] |
Gastric | Circ-DIDO1 | Circ-DIDO1 transfected 293T | Suppressed tumor progression | [193] |
Glioma | Circ-BTG2 | RBP-J-overexpressed- macrophage | Inhibited the progression | [60] |
Ovarian | CircIFNGR2 | CAF | Inhibited the malignant progression | [73] |
PCa | Circ_0030167 | BMSCs | Inhibited the stemness | [195] |
TNBC | Circ-CREIT | / | Overcome doxorubicin resistance | [90] |
OSCC | Cicr-GDI2 | Circ-GDI2-transfected CAL27 cells | Suppressed tumor progression | [58] |
RCC | Circ-SPIRE1 | Circ-SPIRE1 over-expressed cells | Suppressed angiogenesis and metastasis | [202] |
NPC | Circ-FIP1L1 | Guggulsterone treated HNE1 cells | Repressed HUVECs angiogenesis | [203] |